| | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C18H15BrN4 |
| Molar mass | 367.250 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ethylbromazolam is a benzodiazepine derivative [1] which has been sold as a designer drug. [2] [3] [4] It is structurally similar to bromazolam, only differing by the inclusion of an ethyl group instead of a methyl group on the triazole ring. It has been found in combination with its synthetic precursor desalkylgidazepam [5] in samples expected to contain alprazolam only.
Ethylbromazolam has an extremely limited history of human usage. Very little is known about its pharmacological properties, metabolism, and potential toxicity.
It was first detected in the United Kingdom in February 2025, [6] and has subsequently been detected in New Zealand in March 2025 [2] and Australia. [3] [4]